Roberts Acquires Product Licenses
Roberts Pharmaceuticals has concluded two product license acquisitions from Glaxo and SmithKline Beecham. The Glaxo agreement gives Roberts the exclusive US marketing rights to Eltroxin (levothyroxine sodium), a synthetic thyroid drug used to treat hypothyroidism. The acquisition agreement with SmithKline Beecham gives Roberts the UK and Republic of Ireland rights to the antiemetic Maxolon (metoclopromide HCl).
The company reports that both products will fit well into its current product portfolio and add to its therapeutic focus. Roberts plans to launch Eltroxin onto the US market within the next month. It is already approved in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze